Authors' Reply to Michael Auerbach's Comment On: "Frequency and Associated Costs of Anaphylaxis- and Hypersensitivity-Related Adverse Events for Intravenous Iron Products in the USA: An Analysis Using the US Food and Drug Administration Adverse...

Overview

Journal Drug Saf

Specialties Pharmacology
Toxicology

Date 2021 Apr 9

PMID 33835350

Authors

Henry Trumbo

Karolina Kaluza

Syed Numan

Lawrence T Goodnough

Affiliations

Soon will be listed here.

References

Wysowski D, Swartz L, Borders-Hemphill B, Goulding M, Dormitzer C . Use of parenteral iron products and serious anaphylactic-type reactions. Am J Hematol. 2010; 85(9):650-4. DOI: 10.1002/ajh.21794. View

Auerbach M, Ballard H . Clinical use of intravenous iron: administration, efficacy, and safety. Hematology Am Soc Hematol Educ Program. 2011; 2010:338-47. DOI: 10.1182/asheducation-2010.1.338. View

Nathell L, Gohlke A, Wohlfeil S . Reported Severe Hypersensitivity Reactions after Intravenous Iron Administration in the European Economic Area (EEA) Before and After Implementation of Risk Minimization Measures. Drug Saf. 2019; 43(1):35-43. PMC: 6965341. DOI: 10.1007/s40264-019-00868-5. View

Auerbach M . Comment on: Frequency and Associated Costs of Anaphylaxis- and Hypersensitivity-Related Adverse Events for Intravenous Iron Products in the USA: An Analysis Using the US Food and Drug Administration Adverse Event Reporting System. Drug Saf. 2021; 44(5):609-610. DOI: 10.1007/s40264-021-01058-y. View

Potts J, Genov G, Segec A, Raine J, Straus S, Arlett P . Improving the Safety of Medicines in the European Union: From Signals to Action. Clin Pharmacol Ther. 2019; 107(3):521-529. PMC: 7027976. DOI: 10.1002/cpt.1678. View

Trumbo H, Kaluza K, Numan S, Goodnough L . Frequency and Associated Costs of Anaphylaxis- and Hypersensitivity-Related Adverse Events for Intravenous Iron Products in the USA: An Analysis Using the US Food and Drug Administration Adverse Event Reporting System. Drug Saf. 2020; 44(1):107-119. PMC: 7813702. DOI: 10.1007/s40264-020-01022-2. View

Ehlken B, Nathell L, Gohlke A, Bocuk D, Toussi M, Wohlfeil S . Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron (III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ between 2014 and 2017. Drug Saf. 2018; 42(3):463-471. PMC: 6426989. DOI: 10.1007/s40264-018-0769-5. View

Wang C, Graham D, Kane R, Xie D, Wernecke M, Levenson M . Comparative Risk of Anaphylactic Reactions Associated With Intravenous Iron Products. JAMA. 2015; 314(19):2062-8. DOI: 10.1001/jama.2015.15572. View

Szebeni J, Fishbane S, Hedenus M, Howaldt S, Locatelli F, Patni S . Hypersensitivity to intravenous iron: classification, terminology, mechanisms and management. Br J Pharmacol. 2015; 172(21):5025-36. PMC: 4687801. DOI: 10.1111/bph.13268. View

10.

Achebe M, DeLoughery T . Clinical data for intravenous iron - debunking the hype around hypersensitivity. Transfusion. 2020; 60(6):1154-1159. PMC: 7384172. DOI: 10.1111/trf.15837. View

11.

Downing N, Shah N, Aminawung J, Pease A, Zeitoun J, Krumholz H . Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010. JAMA. 2017; 317(18):1854-1863. PMC: 5815036. DOI: 10.1001/jama.2017.5150. View